Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median - Andrea Messori; Marco Chiumente; Daniele Mengato (Therapeutic Advances in Medical Oncology, 2020)